HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Probiotic Oral Care? Beneficial Microbes Spread To New Categories

This article was originally published in The Rose Sheet

Executive Summary

With the global market for probiotics predicted to grow 40% in the next five years, some firms are looking for market-share gains by launching products that expand beyond the traditional areas of digestive health and immunity support to include oral care, sports nutrition and children’s products. Probiotic bath and skin-care products also are emerging.

You may also be interested in...

Science of Beauty: Ganeden Claims “Highest Level” Proof For Anti-Aging Probiotic

Ganeden Biotech is optimistic that evidence backing the efficacy of its anti-aging probiotic Bonicel will drive success of the branded ingredient. As regulators and lawsuits target cosmetics companies over claims, science that can withstand these tests becomes more important.

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Ensuring Leading Position For GSK Consumer Products Touted In Management Shift

GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts